Determining the functional role of TRPC channels in primary cells.
Although the TRPC members of the mammalian transient receptor potential TRP cation channel family were the first to be described in 1995, the depth of knowledge of TRPC channels has fallen behind that of their counterparts in the TRPV and TRPM subfamilies in the intervening years. The complexities and controversies of TRPC channel composition and regulation have hindered their progress as therapeutic targets in the drug discovery environment to date, however embracing these challenges as opportunities may bring TRPC channels to the forefront of the discovery of novel therapies for many diseases. These challenges and opportunities of exploring TRPC channels as therapeutic targets are highlighted and discussed in this review with respect to respiratory diseases.
Li
Su
S
Novartis Institutes for Biomedical Research, Novartis Respiratory Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK. su.li@novartis.com
Gosling
Martin
M
Poll
Chris
C
D017398:Alternative Splicing; D000818:Animals; D004353:Drug Evaluation, Preclinical; D004847:Epithelial Cells / Q000378:metabolism; D006801:Humans; D007962:Leukocytes / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008171:Lung Diseases / Q000188:drug therapy / Q000503:physiopathology; D008322:Mammals; D008564:Membrane Potentials; D009130:Muscle, Smooth / Q000378:metabolism; D020836:Protein Structure, Quaternary; D050052:TRPC Cation Channels / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*
D050052:TRPC Cation Channels